ArticleApplied biochemistry and biotechnology2026
Molecular and Immune Profiling of Sessile Serrated Adenomas/Polyps Reveals Prognostic Genes and Immune Cell Dynamics in Colorectal Cancer Progression.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sessile serrated adenomas/polyps (SSAPs) are precursor lesions in colorectal cancer (CRC) development, exhibiting unique molecular and immunological profiles. Understanding the molecular and immune signatures associated with SSAP tumourigenic potential is critical for improving early detection and prognosis. This study employed RNA sequencing data from SSAPs, adenomatous polyps (APs), hyperplastic polyps (HPs), and control samples. Differential gene expression analysis was conducted using DESeq2, followed by pathway enrichment analysis. Immune cell compositions were determined via computational deconvolution. Survival outcomes were assessed using Kaplan-Meier analysis and multivariate Cox proportional hazard models. A predictive gene panel was developed based on hazard ratios of key genes. SSAPs demonstrated elevated stemness and epithelial-mesenchymal transition (EMT) signatures, suggesting a potential tumourigenic capacity that warrants further investigation. The immune landscape of SSAPs was characterised by increased cytolytic activity, T-cell inflammation scores, and enrichment of immune cell subsets such as T lymphocytes, macrophages, and dendritic cells. Differentially expressed genes (C1QTNF8, SLC2A2, DEPP1, CST2, IFNE, ERFE, and HYAL4) were identified as genes significantly associated with CRC prognosis in the analyzed TCGA dataset. Multivariate Cox analysis revealed that IFNE (HR = 1.44, p = 0.018), ERFE (HR = 1.27, p = 0.008), and HYAL4 (HR = 1.43, p = 0.032) were associated with adverse survival outcomes. An exploratory predictive gene panel combining favourable and adverse prognostic genes was associated with stratification of patients into high- and low-risk groups and with overall survival (p = 0.0038). SSAPs exhibit distinct molecular and immunological features that may be associated with CRC progression. Key candidate genes and immune cell dynamics identified in this study may serve as a starting point for future experimental and clinical studies.
Indexed as
Identifiers
42154145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.